Clinical Evaluation of Practolol, a New Cardioselective Beta-blocking Agent in Angina Pectoris

Sandler, Gerald; Clayton, Gerald

doi:10.1136/bmj.2.5706.399

Cited by 33 publications

(7 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In previous studies practolol has been shown to reduce the frequency of attacks (George, Nagle and Pentecost, 1970;Nestel, 1972) and to increase exercise tolerance (Sandler and Clayton, 1970;Balcon, 1971;Westerlund, 1971). The poor response in these respects in the present study is hard to explain, but might be due to coincidence in this rather small group of patients, the number having been limited by the unforeseen interruption of the trial due to the reports of serious side effects of practolol (Felix et al, 1974;Wright, 1975).…”

Section: Discussionmentioning

confidence: 93%

Double-blind comparison of verapamil and practolol in the treatment of angina pectoris

Fagher¹,

Persson²,

Svensson³

1977

Postgraduate Medical Journal

View full text Add to dashboard Cite

SummaryIn thirteen patients with coronary insufficiency and angina pectoris the therapeutic effects of verapamil, 80 mg three times/day and practolol, 100 mg three times/day, were compared and tested against placebo in a double-blind cross-over fashion. Verapamil proved to be the most efficient drug as regards attack frequency and glyceryl trinitrate consumption as well as physical working capacity, bringing about a statistically significant increase of the exercise tolerance as compared to placebo after a treatment period of four weeks. Verapamil is a good alternative to f-blockers in the prophylactic treatment of angina. Possible modes of action of verapamil in angina pectoris are discussed. The study had to be interrupted because of the reports of side effects of practolol, explaining the small number of patients.

show abstract

Section: Discussionmentioning

confidence: 93%

Double-blind comparison of verapamil and practolol in the treatment of angina pectoris

Fagher¹,

Persson²,

Svensson³

1977

Postgraduate Medical Journal

View full text Add to dashboard Cite

show abstract

“…Practolol is a cardioselective adrenergic beta-receptor antagonist with intrinsic sympathomimetic activity (Dunlop and Shanks, 1968). It is, however, less effective than propranolol in angina pectoris (Sandler and Clayton, 1970;Prichard et al, 1971) and though it is less likely to produce bronchospasm and the so-called negative inotropic effect-namely, myocardial depression-these have been induced (Wiseman, 1971). In addition side effects have included systemic lupus erythematosus (Raftery and Denman, 1973), psoriasis-like rashes (Felix and Ive, 1974), and ocular changes (I.C.I., 1974).…”

Section: Introductionmentioning

confidence: 99%

Double-blind comparison of tolamolol, propranolol, practolol, and placebo in the treatment of angina pectoris.

Jackson¹,

Atkinson²,

Oram³

1975

BMJ

View full text Add to dashboard Cite

“…There is evidence that practolol is safer to use in patients with bronchial asthma ( MACDONALD & MCNEILL 1968;SANDLER & CLAYTON 1970;KBRR & PATEL 1970).…”

mentioning

confidence: 99%

The Action of Practolol on the Isolated Rat Atrium

Refsum

Landmark

1972

Acta Pharmacologica et Toxicologica

View full text Add to dashboard Cite

The β‐receptor antagonism and the effects of practolol on the mechanical and electrical behaviour of isolated rat atria suspended in an organ bath have been investigated. Practolol produced a parallel shift to the right in the log. dose‐response curves of isoprenaline with no decrease in the maximal response, indicating that the antagonism is competitive. The drug was found to exert positive inotropic and chronotropic effects in doses between 10‐8M and 10‐5M. Practolol 10‐4M did not change the threshold for excitation and the threshold for experimentally induced atrial fibrillation to any extent, neither did it prolong the effective refractory period. The results show that practolol has β‐adrenergic receptor blocking properties as well as sympatomimetic properties. The results also indicate that practolol possesses no quinidine‐like or local anaesthetic activity.

show abstract

Clinical Evaluation of Practolol, a New Cardioselective Beta-blocking Agent in Angina Pectoris

Cited by 33 publications

References 27 publications

Double-blind comparison of verapamil and practolol in the treatment of angina pectoris

Double-blind comparison of verapamil and practolol in the treatment of angina pectoris

Double-blind comparison of tolamolol, propranolol, practolol, and placebo in the treatment of angina pectoris.

The Action of Practolol on the Isolated Rat Atrium

Contact Info

Product

Resources

About